SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF ($NASA) is generating significant buzz as investors look to gain exposure to the broader space economy and high-profile private companies like SpaceX ahead of an anticipated IPO. Community members are actively debating the merits of holding the ETF as a diversified, long-term vehicle versus individual sector plays, with intense interest centered on the fund's specific SpaceX allocation and the momentum building around upcoming aerospace launches.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

The Walt Disney Co. is trending as investors digest a mix of cost-cutting restructuring measures, including new rounds of layoffs, alongside ongoing discussions about the company's long-term streaming strategy and future content slate. Community sentiment remains deeply divided, with many market participants expressing frustration over persistent range-bound price action and perceived management missteps, while others are closely monitoring technical indicators and restructuring efforts for potential signs of a turnaround.

Amplify ETF Trust - Amplify Junior Silver Miners ETF

Amplify Junior Silver Miners ETF

Amplify Junior Silver Miners ETF (SILJ) is trending as community members closely monitor whether the sector will finally see a violent 'catch-up' rally to match the historic price appreciation in physical silver. While some investors argue that juniors are heavily undervalued relative to spot prices and represent a 'coiled spring' ahead of upcoming earnings reports, others are exercising caution due to continued price volatility and the persistent underperformance of miners compared to the underlying metal.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle Corp is trending as investors respond to a wave of positive analyst upgrades and PT hikes, fueled by a renewed focus on lithium price recovery and rising demand from the energy storage sector. Community members are actively debating the sustainability of this rally, with many highlighting the stock as a core electrification play while others weigh the risks of cyclical volatility after a period of rapid upward price movement.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing heightened community interest due to a potential short squeeze setup characterized by high short interest and a shrinking float caused by active share repurchases. Investors are closely watching the upcoming earnings report as a possible catalyst, drawing parallels to previous squeeze cycles while debating the impact of the company's AI-focused turnaround strategy.

Vishay Precision Group, Inc. engages in the provision of precision measurement and sensing technologies. The firm serves a diverse array of industries and markets, including industrial, test and measurement, transportation, steel, medical, agriculture, avionics, military and space, and consumer. It operates through the following segments: Sensors, Weighing Solutions, Measurement Systems, and Corporate and Other. The Sensors segment is composed of the foil resistor and strain gage operating divisions. The Weighing Solutions segment consists of specialized modules and systems used to precisely measure weight, force torque, and pressure. The Measurement Systems segment includes specialized systems for steel production, materials development, and safety testing. The company was founded on August 28, 2009 and is headquartered in Malvern, PA.

Vishay Precision Group Inc

Vishay Precision Group is trending as investors bet on its role in the humanoid robotics and physical AI supply chain, with community members closely tracking potential design wins with major industry players. Bullish sentiment is driven by strong order momentum and the company's emergence as a specialized provider of critical sensor infrastructure for next-generation robotics.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is facing significant community division as holders debate whether current price levels represent a generational buying opportunity or the end of the project. Sentiment remains polarized between long-term believers accumulating during the downtrend and skeptics who are increasingly vocal about the lack of price momentum compared to other sectors.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus Inc. is trending as investors focus on its role as a key infrastructure partner for SpaceX, with the community actively discussing a recent 9.99% stake acquisition by Citadel and the company's debt-free balance sheet. Market participants are debating the potential for a short squeeze given the stock's low float and the anticipation surrounding the upcoming SpaceX IPO.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending as investors focus on its role as a specialized edge computing provider for defense and autonomous systems, viewing its recent operational pivot and profitability as a setup for long-term growth. Community discussion remains heavily focused on the company's potential to capture future defense contracts and its appeal as a high-upside infrastructure play in the burgeoning AI and edge computing space.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors weigh the company's strong recent revenue growth and expanding sales force against a broader pullback in biotech stocks. The community is actively discussing the upcoming April 30 PDUFA date for the potential approval of Auvelity in treating Alzheimer's disease agitation, which is widely viewed as a major catalyst for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma Reports First Quarter 2026 Financial Results

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $6.23, for a total value of $103,835.41. Following the sale, the insider directly owned 1,193,173...

Xeris Biopharma (XERS) to Release Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-xeris-pharmaceuticals-inc-stock...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) has earned an average rating of "Moderate Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy r...

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL trimmed its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 83.1% during the third quarter, according to its most recent filing with the Securities...

Apella Capital LLC Acquires 235,897 Shares of Xeris Biopharma Holdings, Inc. $XERS

Apella Capital LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 2,359.0% during the fourth quarter, according to the company in its most recent...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an...

Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

XERS
Xeris Biopharma Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest XERS News

XERSXeris Biopharma Holdings Inc